Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study

Clinical Rheumatology

Volumn 34, Issue 10, 2015, Pages 1687-1695

  Berghen, Nathalie ^a   Teuwen, Laure Anne ^a   Westhovens, Rene ^a   Verschueren, Patrick ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Cyclic citrullinated peptide; Malignancies; Rheumatoid arthritis; TNF a

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; BREAST CARCINOMA; CANCER INCIDENCE; CANCER OF UNKNOWN PRIMARY SITE; CANCER REGRESSION; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; DISEASE DURATION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; LARYNX CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTIPLE MYELOMA; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CARCINOMA; RECTUM CARCINOMA; RHEUMATOID ARTHRITIS; SECOND CANCER; SKIN CANCER; SOLID TUMOR; STANDARDIZED INCIDENCE RATIO; UTERINE CERVIX CARCINOMA; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMORBIDITY; COMPLICATION; INCIDENCE; LYMPHOPROLIFERATIVE DISEASE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADALIMUMAB; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMORBIDITY; ETANERCEPT; FEMALE; HUMANS; INCIDENCE; INFLIXIMAB; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84942369508     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-3026-7     Document Type: Article

References (35)

1. Scott DL, Wolfe F, Huizinga TWJ (2010) Rheumatoid arthritis. Lancet 376:1094–1108
2. Pedersen JK, Kjaer NK, Svendsen AJ, Horslev-Petersen K (2009) Incidence of rheumatoid arthritis from 1995 to 2001: impact of ascertainment from multiple sources. Rheumatol Int 29:411–415
3. Colmegna I, Ohata BR, Menard HA (2012) Current understanding of rheumatoid arthritis therapy. ClinPharmacolTher 4:607–620
4. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. PharmacolTher 117:244–279
5. Scott DL (2012) Biologics-based therapy for the treatment of rheumatoid arthritis. ClinPharmacolTher 91:30–43
6. Raval G, Mehta P (2010) TNF-a inhibitors: are they carcinogenic? Drug Health Patient Saf 2:241–247
7. Smitten AL, Simon TA, Hochberg MC, Suissa S (2008) A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10:R45
8. Heminki K, Sundquist K, Sundquist J (2008) Cancer risk in hospitalized rheumatoid arthritis patients. Rheumatology 47:698–701
9. Keystone EC (2011) Does Anti-tumour necrosis factor alfa therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis? A review of longterm data. J Rheumatol 38:1552–1562
10. Ekström K, Hjalgrim H, Brandt L, Baecklund E, Klareskog L, Ekbom A, Askling J (2003) Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives. Arthritis Rheum 48:963–970
11. Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54:2757–2764
12. Krathen MS, Gottlieb AB, Mease PJ (2010) Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis. J Rheumatol 37:2205–2215
13. Burmester GR, Mease P, Dijkmans BA, Gordon K, Lovell D, Panaccione R, Perez J, Pangan AL (2009) Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 68:1863–1869
14. Solomon DH, Mercer E, Kavanaugh A (2012) Observational Studies on the Risk of Cancer Associated With Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis. Arthritis Rheum 64:21–32
15. Rosenblum H, Amital H (2011) Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 10:563–568
16. Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, Walsh C, Lawson R, Reynolds A, Emery P (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895–1904
17. Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56:1433–1439
18. Wolfe F, Michaud K (2007) Biologic treatment of Rheumatoid Arthritis and the risk of malignancy. Arthritis Rheum 56:2886–2895
19. Nasir A, Greenberg JD (2007) TNF antagonist safety in rheumatoid arthritis. updated evidence from observational registries. Bull NYU HospJt Dis 65:178–181
20. Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W, Listing J, Zink A (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5
21. Le Blay P, Mouterde G, Barnetche T, Morel J, Combe B (2012) Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapie in patients with rheumatoid arthritis: a meta-analysis of registries and systematic review of long-term extension studies. ClinExpRheumatol 30:756–764
22. Dreyer L, Mellemkjær L, Rødgaard Andersen A, Bennett P, EnglingPoulsen U, JuulsgaardEllingsen T, Høiland Hansen T, Vendelbo Jensen D, Linde L, Merete Lindegaard H, Rasmussen Loft AG, Nordin H, Omerovic E, Rasmussen C, Schlemmer A, Tarp U, Lund Hetland M (2013) Incidences of overall and site specific cancers in TNFα inhibitor treated patients with rheumatoid arthritis and other arthritides – a follow-up study from the DANBIO. Ann Rheum Dis 72:79–82
23. Horton S, Buch MH, Emery P (2010) Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations. Drug Healthc Patient Saf 2:101–119
24. Mercer LK, Green AC, Galloway JB, Davies R, Lunt M, Dixon WG, Watson KD, British Society for Rheumatology Biologics Register Control Centre Consortiom DP Symmons KL Hyrich British Society for Rheumatology Biologics Register (2012) The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 71:869–874
25. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF Antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 295:2275–2285
26. http://www.kankerregister.org/
27. Silcocks P (1994) Estimating confidence limits on a standardised mortality ratio when the expected number is not error free. J Epidemiol Community Health 48:313–317
28. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundström C, Klareskog L (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701
29. Mariette X, Gottenberg JE, Ravaud P, Combe B (2011) Registries in rheumatoid arthritis and auto-immune diseases: data from the French registries. Rheumatology 50:222–229
30. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J PharmacolExpTher 301:418–426
31. Hasserjian RP, Chen S, Perkins SL, de Leval L, Kinney MC, Barry TS, Said J, Lim MS, Finn WG, Medeiros LJ, Harris NL, O’Malley DP (2009) Immunomodulator agent-related lymphoproliferative disorders. Mod Pathol 22:1532–1540
32. Ichikawa A, Arakawa F, Kiyasu J, Sato K, Miyoshi H, Niino D, Kimura Y, Takeuchi M, Yoshida M, Ishibashi Y, Nakashima S, Sugita Y, Miura O, Ohshima K (2013) Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol 91:20–28
33. Knowles DM (1999) Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol 12:200–217
34. Dierickx D, Tousseyn T, Sagaert X, Fieuws S, Wlodarska I, Morscio J, Brepoels L, Kuypers D, Vanhaecke J, Nevens F, Verleden G, Van Damme-Lombaerts R, Renard M, Pirenne J, De Wolf-Peeters V, Verhoef G (2013) Single-center analysis of biopsy-confirmed post-transplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors. Leuk Lymphoma 54:2433–2440
35. Feng W, Cohen J, Fischer S, Li L, Sneller M, Goldbach-Mansky R, Raab-Traub N, Delecluse H, Kenney S (2004) Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst 96:1691–1702